NTI 1.89% 5.4¢ neurotech international limited

Ann: Phase II/III ASD Trial Successfully Meets Primary Endpoint, page-41

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 8,420 Posts.
    lightbulb Created with Sketch. 1195
    Fully Finalised Results for this Autism Spectrum Disorder Trial should be close,
    Given that the other one for Rett's has been released already....
 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.